GLPwatch
Papers (10382)
Page 119 of 174, ranked by citation count.
- Weekend therapy in diabetes.
- Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trials.
- A Liraglutide Injection Superimposing a Starvation Acidosis: a Case Report.
- Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review.
- Exploring the Effect and Mechanism of Liraglutide in Treating Depression Based on Network Pharmacology and Experimental Analysis.
- GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.
- Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.
- [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
- One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.
- GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.
- Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways.
- Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.
- Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
- Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial.
- Tirzepatide for diabetes: on track to SURPASS current therapy.
- No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes.
- Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference.
- Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
- Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States.
- Tirzepatide Trial Demonstrates Substantial Weight Loss.
- Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.
- Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
- The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials.
- A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet.
- Liraglutide Is Protective against Brain Injury in Mice with Febrile Seizures by Inhibiting Inflammatory Factors.
- Suppression of the nuclear factor Eny2 increases insulin secretion in poorly functioning INS-1E insulinoma cells.
- Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.
- From needles to pills: oral GLP-1 therapy enters the obesity arena.
- The Effect of Feeding Behavior on Hypothalamus in Obese Type 2 Diabetic Rats with Glucagon-like Peptide-1 Receptor Agonist Intervention.
- Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model.
- Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis.
- Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study.
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
- Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease.
- Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs.
- HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes.
- Efficacy and safety of dulaglutide in patients with absolute insulin deficiency.
- Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.
- Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence.
- Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
- The safety of albiglutide for the treatment of type 2 diabetes.
- Weight Loss Pharmacotherapy: Current and Future Therapies.
- A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.
- IDegLira Improves Metabolic Control in Patients with Type 2 Diabetes Previously Treated with Premix Insulin.
- Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists.
- A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.
- Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry.
- Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
- Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
- The First Triple Agonist for Antiobesity: Retatrutide.
- Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge.
- Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354.
- Neuropsychiatric Effects of Tirzepatide: A Systematic Review and Meta-Analysis.
- A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.
- Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist In Patients with Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.
- Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39).